Search
RenovoRx Inc
RNXTAdd to Watchlist
0.920USD
-0.035-3.67%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
41.45MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.67%
5 Days
-2.50%
1 Month
-5.67%
6 Months
+10.17%
Year to Date
+9.52%
1 Year
-32.35%
Key Figures
0.950Open
0.966High
205.09KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.46%Turnover Ratio
0.955Prev. Close
0.915Low
136.51KTurnover
LossP/E Static
3.68P/B
0.00%Div Yield TTM
-81.85%ROA
1.45052wk High
1.37Volume Ratio
-8.81MNet Profit
45.05MShares
-0.3316EPS TTM
1.03Beta
-100.47%ROE
0.70152wk Low
5.28%Amplitude
85.08%Gross Margin
41.45MMarket Cap
-0.46Reward/Risk
4.47%Risk Rate
TradingKey Stock Score of RenovoRx Inc
Currency: USD Updated: 2026-07-02Key Insights
RenovoRx Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 120 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
RenovoRx Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
RenovoRx Inc Highlights
StrengthsRisks
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.12M.
Undervalued
The company’s latest PE is -2.77, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.02M shares, decreasing 6.55% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 14.10K shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
7.000
Target Price
+632.83%
Upside Space
RenovoRx Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
RenovoRx Inc Info
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
Ticker SymbolRNXT
CompanyRenovoRx Inc
CEOBagai (Shaun R)
Websitehttps://renovorx.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of RenovoRx Inc (RNXT)?
The current price of RenovoRx Inc (RNXT) is 0.92.
What is the symbol of RenovoRx Inc?
The ticker symbol of RenovoRx Inc is RNXT.
What is the 52-week high of RenovoRx Inc?
The 52-week high of RenovoRx Inc is 1.45.
What is the 52-week low of RenovoRx Inc?
The 52-week low of RenovoRx Inc is 0.70.
What is the market capitalization of RenovoRx Inc?
The market capitalization of RenovoRx Inc is 41.45M.
Is RenovoRx Inc (RNXT) currently rated as Buy, Hold, or Sell?
According to analysts, RenovoRx Inc (RNXT) has an overall rating of Buy, with a price target of 7.00.
What is the Earnings Per Share (EPS TTM) of RenovoRx Inc (RNXT)?
The Earnings Per Share (EPS TTM) of RenovoRx Inc (RNXT) is -0.32.